For a general practitioner in Oslo or a physiotherapist in Copenhagen, the final patient of the day is rarely the end of work. The real labor often begins after the door closes, with the slow, meticulous task of translating a conversation into a structured medical note for the electronic health record. It is a universal and exhausting administrative tax on clinical time, one that Oslo-based Noteless was founded in 2023 to automate. By mid-2024, the startup had a simple proposition: turn on a microphone, have a normal consultation, and let an AI generate the note for you [TechFundingNews, Nov 2025].
Now, with a fresh €3.5 million seed round led by Redstone, Noteless is reporting a velocity of adoption that suggests it has struck a nerve. The company says its system has processed more than 3 million patient consultations and is used by around 3,000 clinicians across Norway, Denmark, the UK, Germany, and the Netherlands [TechFundingNews, Nov 2025]. That translates to over 100,000 consultations supported each week [BeBeez International, Nov 2025].
The Wedge: Real-Time Listening, Not Dictation
The product's wedge is its focus on passive listening rather than active dictation. Unlike traditional speech-to-text tools that require a physician to narrate findings, Noteless is designed to operate in the background. A clinician starts a recording at the beginning of a consultation; the system uses speech recognition and natural language processing to listen to the natural dialogue, then automatically generates a formatted clinical note ready for review and copy-pasting into the EHR [F6S, 2026].
The promise is a direct attack on burnout metrics. The company claims the tool can save clinicians up to two hours per day on documentation [TechFundingNews, Nov 2025]. This positions Noteless as a pragmatic efficiency tool with a clear, immediate return on investment for its users, including GPs, specialists, physiotherapists, and psychologists [TechFundingNews, Nov 2025].
Traction and the European Footprint
Growth appears concentrated in Scandinavia but is spreading. The company, which now employs 35 people across Norway, Denmark, and the Netherlands, has built integrations with electronic health record systems used in Norwegian hospitals and the national health portal Helsenorge [BeBeez International, Nov 2025]; [Journal of Medical Internet Research, 2024].
The seed funding, which also included participation from Futurum Ventures and Farvatn Venture, will be used to accelerate this expansion across Europe and further develop the AI models [TechFundingNews, Nov 2025].
The Founders and the Regulatory Context
The founding team brings a blend of technical and healthcare domain expertise. William Vossgård serves as CEO, with Mikkel Slettebø as CTO. Co-founder Sarankan Sivakanesan is a medical doctor, providing an intrinsic clinical lens on product development [Sarankan Sivakanesan - LinkedIn, 2026].
For any clinical documentation tool, the regulatory context is paramount. Noteless has not publicly detailed its regulatory classification or strategy. The company's approach of generating notes for clinician review, rather than making autonomous decisions, likely places it in a lower-risk class, but clarity here will be essential as it moves into larger, more conservative health systems.
Where the Wheels Could Come Off
The clinical AI scribe space is not uncontested. Noteless faces established giants like Nuance Dragon Medical and well-funded startups like Suki AI. Its current advantages appear to be its European focus, a lightweight deployment model, and early traction in specific national health systems. However, several risks loom on the horizon:
- Accuracy and liability. The core risk for any AI scribe is error. Noteless mitigates this by having the clinician review and approve every note.
- Data privacy and sovereignty. Processing millions of sensitive health conversations requires ironclad data governance. The company's ability to assure hospitals and clinics of full GDPR and local compliance will be a key purchasing factor.
- The monetization motion. Converting clinicians who may have started on a free or trial tier into paying enterprise contracts is a different motion than seeding adoption.
The company's most plausible answer to these challenges is its current trajectory: sheer volume of use. Processing over 3 million consultations provides a formidable dataset to continuously improve model accuracy and robustness [TechFundingNews, Nov 2025].
The Next Twelve Months
The immediate roadmap will likely focus on converting its Scandinavian beachhead into durable enterprise contracts while proving expansion in the UK and Germany. Key milestones to watch will be announcements of formal partnerships with large hospital groups or national health services. Given its seed funding and growth rate, a Series A round within the next 12-18 months seems a probable next step.